Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical Study
Clinical trial NCT03368131 · UNKNOWN
Trial details
- NCT number
- NCT03368131
- Sponsor
- Hebei Medical University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-12-01
- Primary completion
- 2019-12-30
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.